Find your local site

Andy Acker, CFA

Global Life Sciences | Portfolio Manager
Andy Acker, CFA | Janus Henderson Investors

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners.

Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation and has 27 years of financial industry experience.

Download hi-res headshot

Articles Written

What’s next for biotech’s M&A boom?
Timely & Topical

What’s next for biotech’s M&A boom?

A regulatory hurdle may delay some merger and acquisition activity in the sector – but is unlikely to stop dealmaking.

Biopharma delivers blockbuster growth
Timely & Topical

Biopharma delivers blockbuster growth

How innovation is driving drug revenue growth in biopharma.

Global Perspectives: Why biotech could be embarking on a new decade of growth
Features & Outlooks

Global Perspectives: Why biotech could be embarking on a new decade of growth

A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science.

Two sides of healthcare, one strong investment case
Timely & Topical

Two sides of healthcare, one strong investment case

The healthcare sector has been resilient through market drawdowns but also benefits from significant long-term growth drivers.

Biotech rides a wave of positive data
Timely & Topical

Biotech rides a wave of positive data

Positive clinical trial data in 2022 could lead to record drug launches over the coming year.

Healthcare stocks show signs of strength
Timely & Topical

Healthcare stocks show signs of strength

Andy Acker discusses how pricing power, growing demand, and an improving outlook for biotech could bolster the sector heading into 2023.